Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Webcasts|March 2, 2026
Adaptive Trial Design and Regulatory Shifts in Biopharma Development
Listen
0:00 / 0:00
Webinar Date/Time: Fri, Mar 27, 2026 11:00 AM EDT
This Drug Digest episode examines how evolving regulatory and quality expectations are reshaping biopharmaceutical development and manufacturing. The episode delivers targeted insights on FDA guidance, adaptive trial design, and compliance strategies shaping biopharma decision-making.
Register Free:
Event Overview:
Across recent biopharma regulatory updates, a clear industry narrative centers around evolving quality and regulatory expectations. In this episode of PharmTech Drug Digest, we examine how dynamic regulatory and quality frameworks are shaping biopharmaceutical development and compliance. From updated vaccine schedule guidance influencing demand and safety dialogue to new FDA draft guidances embracing adaptive trial design and modern evidence standards, these shifts elevate quality expectations, streamline regulatory pathways, and impact clinical development strategies across the biopharma industry.
Key Learning Objectives:
- Evolving FDA and global quality standards
- Adaptive and Bayesian trial designs
- Impact of immunization guidance on compliance
- Risk-based quality and evidence strategies
Who Should Attend:
- Quality assurance professionals
- Regulatory affairs leaders
- CMC and technical operations specialists
- Clinical development scientists
Register Free:
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.